Vanguard Group
LYRA

Vanguard Group’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Vanguard Group’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,754
Closed -$189K – 4376
2025
Q3 		$189K Sell
28,754
-424
-1% -$3.11K ﹤0.01% 4136
2025
Q2 		$261K Sell
29,178
-6,134
-17% -$50.9K ﹤0.01% 4041
2025
Q1 		$222K Sell
35,312
-436
-1% -$4.08K ﹤0.01% 4051
2024
Q4 		$368K Buy
35,748
+163
+0.5% +$1.79K ﹤0.01% 4012
2024
Q3 		$457K Buy
35,585
+967
+3% +$14.2K ﹤0.01% 3992
2024
Q2 		$479K Buy
34,618
+4,988
+17% +$564K ﹤0.01% 4023
2024
Q1 		$9.21M Buy
29,630
+8,201
+38% +$2.19M ﹤0.01% 3007
2023
Q4 		$5.61M Buy
21,429
+4,142
+24% +$750K ﹤0.01% 3240
2023
Q3 		$3.38M Buy
17,287
+1,468
+9% +$263K ﹤0.01% 3411
2023
Q2 		$3.25M Hold
15,819
– – ﹤0.01% 3486
2023
Q1 		$1.59M Hold
15,819
– – ﹤0.01% 3758
2022
Q4 		$2.48M Buy
15,819
+7
+0% +$1.39K ﹤0.01% 3586
2022
Q3 		$3.96M Buy
15,812
+2,299
+17% +$680K ﹤0.01% 3437
2022
Q2 		$3.82M Buy
13,513
+9,138
+209% +$2.49M ﹤0.01% 3517
2022
Q1 		$879K Hold
4,375
– – ﹤0.01% 4250
2021
Q4 		$954K Sell
4,375
-26
-0.6% -$8.35K ﹤0.01% 4280
2021
Q3 		$2.01M Hold
4,401
– – ﹤0.01% 4051
2021
Q2 		$1.77M Buy
4,401
+163
+4% +$74.3K ﹤0.01% 4003
2021
Q1 		$2.46M Buy
4,238
+764
+22% +$477K ﹤0.01% 3819
2020
Q4 		$1.98M Buy
3,474
+441
+15% +$249K ﹤0.01% 3661
2020
Q3 		$1.7M Buy
3,033
+2,340
+338% +$1.46M ﹤0.01% 3532
2020
Q2 		$393K Buy
+693
New +$507K ﹤0.01% 3821

Other funds holding LYRA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Vanguard Group's LYRA Position: Q4 2025 in Review

Vanguard Group sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2025, closing a stake of 28,754 shares — an estimated $189K sold.

Vanguard Group first reported a position in LYRA in Q2 2020 and held it in 22 quarters. The position peaked at $9.21M in Q1 2024. 23 funds tracked by Wall St. Rank hold LYRA as of Q4 2025.

  • Vanguard Group reported no remaining LYRA THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Vanguard Group sold 28,754 LYRA THERAPEUTICS INC shares in Q4 2025, an estimated $189K.
  • Vanguard Group first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 22 quarters.
  • Vanguard Group's LYRA THERAPEUTICS INC position peaked at $9.21M in Q1 2024.
  • 23 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.